SUZHOU, China--(satPRNews.com)--Suzhou Alphamab Co., Ltd. announced today the appointment of Claudia Lin, Ph.D. as General Manager of Alphamab (Jiangsu) Biopharmaceuticals Co., Ltd., a newly established subsidiary with an initial funding of $300 million to manufacture and develop multiple novel biologics in the Alphamab pipeline. Alphamab also appointed Mike Liu, Ph.D., MBA as its Executive Vice President to lead global business development.
Before joining Alphamab, Dr. Lin was Vice President at Innovent Biologics, responsible for GMP compliance and Quality management. She was instrumental in building the strategy, team, and Quality systems to establish a world-class GMP operation and support the clinical development of pipeline products. Prior to Innovent, Dr. Lin served as Head of Quality Assurance for Bayer Healthcare Biotech division, responsible for all products in clinical development stages through to initial product launch. In her earlier career, she held various Quality leadership positions in Genentech/ROCHE including QA and QC functions for biological products at the phase of clinical trial, global product launch, and commercialization, including Avastin, Herception Perjeta, and TDM1.
Prior to Alphamab, Dr. Liu was Head of Global Business Development at Hengrui Pharmaceuticals, where he closed dozens of licensing and partnership agreements with leading multi-national and Chinese companies, including the $795-million out-licensing deal with Incyte for PD-1 mAb and in-licensing of Rolapitant from TESAro. Previously, Dr. Liu held increasing responsibilities for global commercial development at Alexion Pharmaceuticals and licensing & business development at Purdue Pharma L.P.
“We are delighted to have Dr. Lin and Dr. Liu join us,” said Dr. Ting Xu, Chairman and CEO of Alphamab. “They are bringing in very valuable expertise and experience in biologics quality management, manufacturing, and business development. As Alphamab grows rapidly, their addition will enable us to expand our global footprint.”
About Suzhou Alphamab Co., Ltd.
Suzhou Alphamab Co., Ltd., founded in 2009, is a leading biotechnology company in China FOCused on the discovery, development and manufacture of innovative biologics therapeutics. With multiple in-house proprietary platforms in protein engineering, antibody screening and bi-specifics, Alphamab and its subsidiaries have created a robust pipeline of over 20 innovative biologics programs in immune-oncology, infertility, infectious diseaSES and several other areas. Alphamab is striving to develop 1st-in-class or best-in-class medicine to address unmet medical needs globally.
For more information: http://www.alphamab.com
Contacts
Suzhou Alphamab Co., Ltd.
Junhong Zhang, +86-512-65951826
junhongzhang@alphamab.com
Source: Alphamab Appoints New Senior Executives in Operation and Business Development
Link: Alphamab Appoints New Senior Executives in Operation and Business Development